Hypercalcemia is a condition caused by above normal levels of calcium in the body, with serum calcium level greater than 2.6 mmol/L. It is a life threatening metabolic disorder associated with neoplastic diseases and occurs in 10% to 20% of all adults suffering from cancer; particularly lung and breast cancer, and myeloma.
The increasing instances of surgical procedures, such as hip and knee replacements, will increase the risk of hypercalcemia and drive the growth prospects for the global hypercalcemia treatment market in the upcoming years. The study also shows that the prevalence of broken bone repair surgeries, cardiovascular procedures, percutaneous coronary interventions, joint replacement surgeries, knee replacement surgeries, hip replacement surgeries, and cases of coronary artery bypass grafting will increase the chances of developing hypercalcemia post surgeries. Consequently, the demand for hypercalcemia treatment drugs will also increase during the predicted period.
The growing preference for combination therapy is estimated to drive the growth prospects for the global hypercalcemia treatment market until the end of 2023. The adoption rate and preference for hypercalcemia drugs is increasing in developed countries with the growing use of hypercalcemia drugs in combination with other therapies. For instance, researchers have evaluated the use of combination drugs, which includes pamidronate and calcitonin. Additionally, it has also been observed that the reduction in elevated serum parathyroid hormone (PTH) levels and the improvement of bone mineral density can be achieved using denosumab (DMAb) and calcitriol. Such combination therapies will lead to a new therapeutic strategy to reverse severe bone loss due to therapy-resistant SHPT in individuals with CKD.
In 2018, the global Hypercalcemia Treatment market size was 8590 million US$ and it is expected to reach 19100 million US$ by the end of 2025, with a CAGR of 10.5% during 2019-2025.
This report focuses on the global Hypercalcemia Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hypercalcemia Treatment development in United States, Europe and China.
The key players covered in this study
AbbVie
Amgen
Merck
Novartis
OPKO Health
...
Market segment by Type, the product can be split into
Bisphosphonates
Glucocorticoids
Calcimimetic Agents
Market segment by Application, split into
Mild Hypercalcemia
Moderate Hypercalcemia
Severe Hypercalcemia
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Hypercalcemia Treatment status, future forecast, growth opportunity, key market and key players.
To present the Hypercalcemia Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Hypercalcemia Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Summary:
Get latest Market Research Reports on Hypercalcemia Treatment . Industry analysis & Market Report on Hypercalcemia Treatment is a syndicated market report, published as Global Hypercalcemia Treatment Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Hypercalcemia Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.